Cantor Fitzgerald Reiterates Neutral Rating, $1 Price Target on TherapeuticsMD (TXMD) on Failed Acquisition
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated a Neutral rating and $1.00 price target on TherapeuticsMD (NASDAQ: TXMD), following Athene Merger's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
